Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 23;38(1):71–80. doi: 10.1200/JCO.19.01586

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by American Society of Clinical Oncology

PMC Copyright notice

FIG 3. — Pathologic and genomic correlates of response. (A) Oncoprint showing the genomic landscape of advanced adrenocortical carcinomas treated with pembrolizumab in this study, as identified by Memorial Sloan Kettering–Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). (B, C, and D) Tumor mutation burden, tumor microsatellite-high/mismatch repair-deficient (MSI-H/MMR-D) status, and tumor programmed death-ligand 1 (PD-L1) status in relation to objective response to pembrolizumab. In correlative analyses, there was no association between genetic alterations, tumor mutation burden, tumor MSI-H/MMR-D status, or tumor PD-L1 status with objective response. Mut/Mb, mutations/megabase; PD, progression of disease by RECIST v1.1; PR, partial response by RECIST v1.1; SD, stable disease by RECIST v1.1; TIL, tumor-infiltrating lymphocyte.